STRATEC intends to modify its legal form to that of a European company

DGAP-News: STRATEC Biomedical AG / Key word(s): Miscellaneous

12.04.2018 / 08:17

The issuer is solely responsible for the content of this announcement.


STRATEC intends to modify its legal form to that of a European company

Birkenfeld, April 12, 2018

The Management Board and the Supervisory Board of STRATEC Biomedical AG have decided to propose the transformation of STRATEC Biomedical AG into a European company (Societas Europaea, SE), to be known in future as STRATEC SE, at the Annual General Meeting on May 30, 2018. As part of this change, the name supplement “Biomedical” will be dropped in the future.

In the opinion of the Management Board and the Supervisory Board, the planned change of legal form is in keeping with STRATEC’s identity as an internationally oriented company. The internationalization of STRATEC has further accelerated in recent years, in particular through the subsidiaries acquired and founded in other member states of the European Union, as well as through the revenue growth achieved with international customers. As of December 31, 2017, group-wide, 57% of employees are based abroad. In addition, for the fiscal year 2016, 87% of sales revenue was generated with customers outside of Germany. The transformation into an SE is therefore a consistent step which also offers the possibility of further optimizing STRATEC structures to the expected future international corporate growth.

With the transformation into an SE, the shareholders of STRATEC Biomedical AG automatically become shareholders of STRATEC SE. The rights of the shareholders will remain unchanged.

The conversion of legal form requires the approval of the shareholders. This is planned to be secured at the Annual General Meeting on May 30, 2018.

The shareholders of STRATEC Biomedical AG will receive detailed information on this planned legal form transformation with the invitation to the Annual General Meeting.

STRATEC Biomedical AG ( designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. Furthermore, the company offers sample preparation solutions, integrated laboratory software, and complex consumables for diagnostic and medical applications. STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks, and research institutes around the world. STRATEC develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.

Further information is available from:
STRATEC Biomedical AG
Jan Keppeler, Investor Relations & Corporate Communications
Gewerbestr. 37, 75217 Birkenfeld
Tel: +49 7082 7916-6515
Fax: +49 7082 7916-9190

12.04.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

End of News DGAP News Service

show this